ABSI Share Price Performance
US$3.55
0.22 (6.61%)
56.3% undervalued intrinsic discount
US$8.11
Fair Value
Price US$3.55
AnalystConsensusTarget US$8.11
Fair ValueUS$8.11
Share Pricen/a
Absci Corporation Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 58 Fair Values set on narratives written by author
ABSI Community Narratives
AN
Fair Value US$8.11 56.3% undervalued intrinsic discount
Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development
Catalysts About Absci Absci uses an AI driven platform to design and develop novel biologic drugs, advancing its own pipeline and partnered programs. What are the underlying business or industry changes driving this perspective?Read more
34
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$8.11
56.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
175.28% p.a.
Profit Margin
0.16%
Future PE
194.74x
Price in 2028
US$0.07
Trending Discussion
Recently Updated Narratives
AN
Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development
Fair Value: US$8.11 56.3% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Absci Corporation Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.76
- -2,494.96%
- -4,071.19%
- 0.7%
About ABSI
- Founded
- 2011
- Employees
- 157
- CEO
- WebsiteView website
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
